Sign in Create account

Beryl Drugs Ltd.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524606
₹25.65
▲ 1.10 (4.48%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
49/100
Moderate
Valuation
84/100
Undervalued
Momentum
52/100
Neutral

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹13 Cr
PE (TTM)
20.7
Industry median 36.1 (152 companies)
Price to Book
1.3
PEG (TTM)
0.1
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-27.5
Free Cash Flow
₹-0 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
1000.00%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
81.70%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
8.29%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
952.38%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
52.21%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.55
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.24
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
3.58
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
3.03%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
4.55%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
5.13%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
4.31%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
8.94%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
6.52%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.24)
  • No Return on equity is 15% or more (6.5%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

3 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
4.5%
Low 24.3700 · High 26.4900
1W return
7.0%
Low 21.0700 · High 26.5000
1M return
9.2%
Low 21.0100 · High 26.5000
52W return
-27.5%
Low 21.0100 · High 26.9500
Lifetime High ₹45.4500 (July 30, 2015)
Lifetime Low ₹0.9300 (Jan. 25, 2007)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
24.6
10D
24.2
20D
24.2
50D
25.9
100D
27.7
200D
29.2

Delivery and volume

Day avg. delivery
63.6%
Week avg. delivery
74.1%
Month avg. delivery
73.9%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

25.50
Pivot
First resistance26.64
Second resistance27.62
Third resistance28.76
First support24.52
Second support23.38
Third support22.40
Day RSI57.4
Day MFI71.6
Day MACD-0.25
Day MACD signal-0.56

Beta

1M0.41
3M0.69
1Y0.69
3Y0.58

Price change analysis

↑ 9.2%
Over 1 Month
LowHigh
21.0126.50
↓ -27.5%
Over 3 Months
LowHigh
21.0126.95
↓ -27.5%
Over 6 Months
LowHigh
21.0126.95
↓ -27.5%
Over 1 Year
LowHigh
21.0126.95
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 20.7 (own history: 19.3–1180.0)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹7 Cr
Net profit (June 30, 2026)
₹0 Cr
Basic EPS (June 30, 2026)
₹0.4400

Ranks #173 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter27.82%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings increased from 27.48% to 27.82% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 495 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
8 Apr 2026 PRADEEP KUMAR JAIN Bulk Buy 30,000 26.1000 BSE
16 Dec 2025 SAMIR NARENDRA GUPTA Bulk Sell 99,921 22.5000 BSE
16 Dec 2025 PRADEEP KUMAR JAIN Bulk Buy 100,000 22.5000 BSE
28 Feb 2025 NARENDRAKUMAR BHAGWANDAS GUPTA Bulk Sell 100,000 24.8500 BSE
28 Feb 2025 SAMIR NARENDRA GUPTA Bulk Buy 100,001 24.8500 BSE
9 Sep 2024 NARENDRAKUMAR BHAGWANDAS GUPTA Bulk Sell 38,038 43.2300 BSE
6 Sep 2024 NARENDRAKUMAR BHAGWANDAS GUPTA Bulk Sell 74,475 38.6000 BSE
10 Jun 2024 KRUNALKUMAR KANUJI THAKOR Bulk Buy 23,893 41.5700 BSE
10 Jun 2024 KRUNALKUMAR KANUJI THAKOR Bulk Sell 36,980 41.4700 BSE
1 Apr 2024 HINDON TRADERS & BROKERS PRIVATE LIMITED Bulk Sell 85,000 28.5200 BSE

All bulk and block deals →

Corporate Announcements

All 9 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Sep 2026 AGM/EGM Beryl Drugs Ltd - 524606 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep 2026 Insider Trading / SAST Beryl Drugs Ltd - 524606 - Closure of Trading Window
29 Sep 2026 AGM/EGM Beryl Drugs Ltd - 524606 - PROCEEDINGS OF 33RD ANNUAL GENERAL MEETING HELD ON 29TH SEPTEMBER, 2026
29 Sep 2026 AGM/EGM Beryl Drugs Ltd - 524606 - Shareholder Meeting / Postal Ballot-Outcome of AGM
29 Sep 2026 Company Update Beryl Drugs Ltd - 524606 - Approval For Increase In The Limit Of Material Related Party Transactions With M/S. Aminova Infusions Pvt. Ltd.
6 Sep 2026 Company Update Beryl Drugs Ltd - 524606 - Announcement under Regulation 30 (LODR)-Newspaper Publication
3 Sep 2026 Corp. Action Beryl Drugs Ltd - 524606 - RECORD DATE FOR THE PURPOSE OF 33RD ANNUAL GENERAL MEETING
2 Sep 2026 Board Meeting Beryl Drugs Ltd - 524606 - Board Meeting Outcome for OUTCOME OF BOARD MEETING
2 Sep 2026 Corp. Action Beryl Drugs Ltd - 524606 - ANNUAL BOOK CLOSURE

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.24)
  • Healthy liquidity (Current Ratio 1.55)
  • Strong revenue growth YoY (52.2%)

Weaknesses

  • Low Return on Equity (6.5%)
  • Thin net profit margin (3.0%)

Opportunities

  • PEG below 1 (0.12) -- earnings growth outpacing its own valuation

Threats

  • Down 27.5% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Beryl Drugs Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.